2011/614/EU: Decision of the European Parliament of 10 May 2011 on discharge in respect of the implementation of the budget of the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines for the financial year 2009
Date: 2011-05-10
Institutions: European Parliament
Subjects: budgetary discharge, financial year, general budget (EU), innovation, joint venture, medicinal product, pharmaceutical industry




L_2011250EN.01025001.xml










27.9.2011   


EN


Official Journal of the European Union


L 250/250








            DECISION OF THE EUROPEAN PARLIAMENT
         
of 10 May 2011
         
on discharge in respect of the implementation of the budget of the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines for the financial year 2009
(2011/614/EU)


THE EUROPEAN PARLIAMENT,






—


having regard to the final annual accounts of the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines for the financial year 2009,










—


having regard to the Court of Auditors’ report on the annual accounts of the Innovative Medicines Initiative Joint Undertaking for the financial year ended 31 December 2009, together with the replies of the Joint Undertaking (1),










—


having regard to the Council’s recommendation of 15 February 2011 (05894/2011 — C7-0051/2011),










—


having regard to Article 276 of the EC Treaty and Article 319 of the Treaty on the Functioning of the European Union,










—


having regard to Council Regulation (EC, Euratom) No 1605/2002 of 25 June 2002 on the Financial Regulation applicable to the general budget of the European Communities (2), and in particular Article 185 thereof,










—


having regard to Council Regulation (EC) No 73/2008 of 20 December 2007 setting up the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines (3), and in particular Article 11(4) thereof,










—


having regard to Commission Regulation (EC, Euratom) No 2343/2002 of 19 November 2002 on the framework Financial Regulation for the bodies referred to in Article 185 of Council Regulation (EC, Euratom) No 1605/2002 on the Financial Regulation applicable to the general budget of the European Communities (4), and in particular Article 94 thereof,










—


having regard to Rule 77 of, and Annex VI to, its Rules of Procedure,










—


having regard to the report of the Committee on Budgetary Control (A7-0129/2011),












1.


Grants the Executive Director of the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines discharge in respect of the implementation of the Joint Undertaking’s budget for the financial year 2009;










2.


Sets out its observations in the resolution below;










3.


Instructs its President to forward this Decision and the resolution that forms an integral part of it to the Executive Director of the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines, the Council, the Commission and the Court of Auditors, and to arrange for their publication in the Official Journal of the European Union (L series).









The President

Jerzy BUZEK
            



The Secretary-General

Klaus WELLE
            





(1)  
            OJ C 342, 16.12.2010, p. 15.

(2)  
            OJ L 248, 16.9.2002, p. 1.

(3)  
            OJ L 30, 4.2.2008, p. 38.

(4)  
            OJ L 357, 31.12.2002, p. 72.






            RESOLUTION OF THE EUROPEAN PARLIAMENT
         
of 10 May 2011
         
with observations forming an integral part of its Decision on discharge in respect of the implementation of the budget of the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines for the financial year 2009


THE EUROPEAN PARLIAMENT,






—


having regard to the final annual accounts of the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines for the financial year 2009,










—


having regard to the Court of Auditors’ report on the annual accounts of the Innovative Medicines Initiative Joint Undertaking for the financial year ended 31 December 2009, together with the replies of the Joint Undertaking (1),










—


having regard to the Council’s recommendation of 15 February 2011 (05894/2011 — C7-0051/2011),










—


having regard to Article 276 of the EC Treaty and Article 319 of the Treaty on the Functioning of the European Union,










—


having regard to Council Regulation (EC, Euratom) No 1605/2002 of 25 June 2002 on the Financial Regulation applicable to the general budget of the European Communities (2), and in particular Article 185 thereof,










—


having regard to Council Regulation (EC) No 73/2008 of 20 December 2007 setting up the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines (3), and in particular Article 11(4) thereof,










—


having regard to the Financial Rules of the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines adopted by Decision of its Governing Board on 2 February 2009,










—


having regard to Commission Regulation (EC, Euratom) No 2343/2002 of 19 November 2002 on the framework Financial Regulation for the bodies referred to in Article 185 of Council Regulation (EC, Euratom) No 1605/2002 on the Financial Regulation applicable to the general budget of the European Communities (4), and in particular Article 94 thereof,










—


having regard to Rule 77 of, and Annex VI to, its Rules of Procedure,










—


having regard to the report of the Committee on Budgetary Control (A7-0129/2011),










A.


whereas the Court of Auditors stated that it has obtained reasonable assurances that the annual accounts for the financial year 2009 are reliable and that the underlying transactions are legal and regular,










B.


whereas the Innovative Medicines Initiative Joint Undertaking was set up in February 2007 to significantly improve the efficiency and effectiveness of the drug development process with the long-term aim that the pharmaceutical sector produces more effective and safer innovative medicines,










C.


whereas the Joint Undertaking is in a start-up phase and had not yet fully established its internal control and financial reporting systems by the end of 2009,






Implementation of the budget









1.


Notes that the Joint Undertaking final 2009 budget included commitment appropriations of EUR 82 000 000 and payment appropriations of EUR 82 000 000; further acknowledges that the utilisation rates for commitment and payment appropriations were 97 % and 1 % respectively;












2.


Recognises that the Joint Undertaking is still in a start-up period; is, nevertheless, concerned that the rate for payment appropriations was only 1 %;





Members’ contribution









3.


Calls on the Joint Undertaking to harmonise the presentation of members’ contributions in the accounts under the guidance of the Commission;












4.


Calls, in addition, on the Joint Undertaking to further develop provisions on membership and co-financing and, in particular, on:






—


the arrangements for the accession of new members,










—


the in-kind contributions by members,










—


the terms and conditions under which the Joint Undertaking may audit the contributions of the members,










—


the conditions under which the Governing Board may approve co-financing;









Internal control systems









5.


Urges the Joint Undertaking to complete the implementation of its internal controls and financial information system;












6.


Calls, in addition, on the Joint Undertaking to include in its Financial Rules a specific reference to the powers of the Internal Audit Service (IAS) as its Internal Auditor, on the basis of the provision set out in the framework Financial Regulation for Community bodies;












7.


Considers, in particular, that the role of the IAS as Internal Auditor should be to advise the Joint Undertaking on dealing with risks, by issuing independent opinions on the quality of management and control systems and by issuing recommendations for improving the conditions of implementation of operations and promoting sound financial management; considers it to be also essential that the Joint Undertaking submit to the discharge authority a report drawn up by its Executive Director summarising the number and the type of internal audits conducted by the Internal Auditor, the recommendations made and the actions taken regarding these recommendations;












8.


Is of the opinion that, in view of the size of its budget and the complexity of its tasks, the Joint Undertaking should establish an audit committee, reporting directly to the Governing Board;





Lack of host agreement









9.


Urges the Joint Undertaking to rapidly conclude a host agreement with Belgium concerning office accommodation, privileges and immunities and other support to be provided by Belgium to the Joint Undertaking as provided by the Regulation (EC) No 73/2008 setting up the Joint Undertaking.






(1)  
            OJ C 342, 16.12.2010, p. 15.

(2)  
            OJ L 248, 16.9.2002, p. 1.

(3)  
            OJ L 30, 4.2.2008, p. 38.

(4)  
            OJ L 357, 31.12.2002, p. 72.